TrialThe oncologist2021

Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial.

Enrique Grande et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.